Best AI Tools for Clinical Trial Patient Recruitment in 2026

Patient recruitment is still the single biggest reason clinical trials run late. Nearly 80% of trials miss their original enrollment timeline, and the tools trying to fix that split into a few distinct jobs: EHR-based matching engines that mine structured and unstructured patient records at scale (Tempus's Deep 6 AI, ConcertAI, Mendel), oncology-specific copilots built for cancer center coordinators (Triomics, Massive Bio), site selection and feasibility platforms sponsors use before a protocol is even finalized (H1, Reify Health's StudyTeam), marketplaces and diversity-focused outreach platforms that widen who gets asked to enroll (Inato, Paradigm Health, Antidote, Acclinate), and one open-source research tool from the NIH that most vendors on this list either cite or build on (TrialGPT). This guide ranks 13 of them by the job they actually do, not a generic AI list repackaged for life sciences.

Updated July 2026. Every tool below was evaluated on its actual recruitment function (patient matching, chart abstraction, site selection, or outreach), and claims were checked against vendor press releases, peer-reviewed studies, or independent coverage current as of July 2026. Nearly every enterprise vendor on this list is quote-based with no public rate card, a pattern this guide states plainly rather than papering over with invented numbers. None of this is medical, legal, or regulatory advice: matching a patient to a trial is not the same as determining eligibility, and every tool here still routes final decisions through an investigator and an IRB.

What Changed in 2026

The 2026 market moved beyond isolated matching demos toward larger networks, operational platforms, and stronger real-world evidence.

• Tempus finished folding Deep 6 AI (acquired March 2025) into its oncology trial-matching stack, extending reach to more than 750 provider sites and over 30 million patient records for real-time EHR mining, per BiopharmaTrend.
• Triomics raised a $22 million Series B in May 2026 and, in January 2026, launched its PRISM matching platform at Mount Sinai's Tisch Cancer Center, joining Memorial Sloan Kettering, MD Anderson, Yale Cancer Center, and Texas Oncology, per Mount Sinai.
• Massive Bio published a peer-reviewed prospective study in April 2026 covering 3,804 metastatic cancer patients, then previewed a broader "Reticulum Nexus" AI operating system for oncology access at ASCO 2026, per BusinessWire.
• ConcertAI launched Accelerated Clinical Trials (ACT), an agentic platform built on its CARAai engine, in February 2026, then expanded its CancerLinQ trial-matching capability in May 2026, per HLTH.
• Paradigm Health, backed by a $203 million Series A, kept expanding its PACT Collective diversity coalition across a research-ready provider network spanning 2,100 care locations, per Fierce Healthcare.
• The FDA's draft Diversity Action Plan guidance, which would have required sponsors to submit formal diversity enrollment plans for certain studies, was quietly pulled from the agency's website following a 2025 executive order on DEI, leaving sponsors without a finalized federal framework even as diversity-focused vendors keep building toward it, per AJMC.

Key Facts

• Nearly 80% of clinical trials fail to hit their original enrollment timeline, and 9 out of 10 end up doubling that timeline to reach target enrollment, per the University of California's research office.
• A single day of trial delay costs sponsors roughly $40,000 in direct trial costs and translates to about $800,000 in unrealized prescription drug sales, per the Tufts Center for the Study of Drug Development's updated 2024 estimate, published in Therapeutic Innovation & Regulatory Science.
• Nearly 40% of the US population belongs to a racial or ethnic minority, yet White participants still make up 80% to 90% of clinical trial groups, per FDA guidance summarized by RTI Health Solutions.
• TrialGPT, the NIH's open-source large language model for eligibility screening, retrieves over 90% of relevant trials while reviewing less than 6% of a site's full trial list, and cut patient screening time by 42.6% in pilot testing, per the peer-reviewed study on PMC/Nature Communications.
• Triomics' oncology trial-matching copilot increased trial matches by 40% and enrollments by more than 30%, while cutting chart review time by 67%, across cancer centers including Memorial Sloan Kettering and MD Anderson, per PR Newswire.
• Massive Bio's AI matching platform found trial matches roughly four times faster than conventional methods in a prospective study spanning 3,804 metastatic cancer patients and generating more than 17,000 oncologist-confirmed matches, per BusinessWire.

Quick Comparison Table

Org-Type Fit Matrix

Use this as a first filter. "Strong fit" means the deployment model and buying process actually match how an organization that size procures software.

Sizing and Persona Table

---

1. Tempus (Deep 6 AI): Broadest EHR-Scale Matching Network

Tempus acquired Deep 6 AI in March 2025 and has spent the time since folding its EHR-mining engine into a broader oncology data platform. The core capability hasn't changed: Deep 6 AI reads both structured fields (ICD-10 codes, demographics) and unstructured notes (pathology reports, physician narratives) in real time to surface eligible patients in minutes instead of the weeks a manual chart review takes.

Pricing: No public list price. Deals are negotiated per health system or sponsor engagement, per BiopharmaTrend's coverage of the acquisition.

Best for: Large health systems and pharma sponsors that need EHR-scale patient discovery across hundreds of sites, not a single-center pilot.

---

2. ConcertAI: Agentic AI Across the Whole Recruitment Funnel

ConcertAI's bet is that recruitment shouldn't be one tool bolted onto a separate feasibility tool bolted onto a separate site-selection tool. Its Accelerated Clinical Trials (ACT) platform, launched in February 2026 on top of its CARAai agentic engine, deploys specialized agents across literature review, protocol design, feasibility analysis, site selection, and patient matching in one workflow, drawing on more than 13 million patient records.

Pricing: No public rate card. ConcertAI sells enterprise engagements scoped to trial portfolio size, per ConcertAI's own ACT announcement.

Best for: Enterprise pharma sponsors running multiple concurrent trials who want feasibility, site selection, and matching handled by one connected AI layer.

---

3. Mendel (Hypercube): Chart Abstraction Meets Trial Matching

Mendel's flagship product, Hypercube, starts from a different premise than most matching tools: the real bottleneck isn't finding candidate trials, it's the hundreds of hours spent abstracting messy clinical data before any matching can happen. Hypercube automates chart review and lets clinical teams query patient cohorts in natural language, then apply that same structured data to trial matching.

Pricing: Not publicly listed. Mendel sells to pharma and CRO teams on a custom, engagement-scoped basis, per Meta's AI blog on Mendel's use of Llama.

Best for: Pharma and CRO teams whose recruitment bottleneck is chart review and cohort assembly, not just trial search.

---

4. Triomics (PRISM): The Coordinator-Facing Oncology Copilot

Triomics built PRISM specifically for the person actually doing pre-screening: an oncology research coordinator staring at a stack of charts. PRISM, powered by Triomics' own OncoLLM, reads patient records, identifies eligible trials, and returns an itemized rationale with source citations, so a coordinator can verify the match instead of trusting a black box.

Pricing: Not publicly listed; deployed through institutional agreements with cancer centers, per Triomics' Series B announcement.

Best for: Academic and NCI-designated cancer centers wanting a matching tool their own coordinators can verify and trust, not just an automated black box.

---

5. Massive Bio: Matching for Patients Outside Academic Centers

Most matching tools assume a patient is already inside a health system with a rich EHR. Massive Bio's network works the other way: it plugs into community oncology practices, where most cancer patients are actually treated, and uses a neuro-symbolic, multi-agent AI system to match them into trials that would otherwise require a referral to a distant academic center.

Pricing: Not publicly listed; access typically runs through partner and referral network agreements, per Massive Bio's study announcement.

Best for: Community oncology practices and patient navigators trying to connect patients to trials they'd otherwise never hear about.

---

6. H1: Site Selection and Feasibility, Not Patient Matching

H1 solves a different, earlier problem than the tools above: before you can match a single patient, you need to know which sites and investigators can actually run the protocol. H1's real-world HCP and site data addresses what it calls the "feasibility gap," the disconnect between planning a trial and having integrated country-, site-, and investigator-level data to plan it well.

Pricing: Not publicly listed; sold as an enterprise data platform subscription, per H1's own coverage of the feasibility gap.

Best for: Sponsors and CROs who need data-driven site selection and feasibility analysis before a protocol is finalized, not a matching engine after the fact.

---

7. Reify Health (StudyTeam): Portfolio-Wide Enrollment Visibility

Reify Health's StudyTeam platform, under the OneStudyTeam brand, takes the site's perspective: it's the tool a research coordinator logs into to pre-screen patients and the tool a sponsor uses to see enrollment status across every site in a trial at once. It's less a matching algorithm and more the operational layer that makes recruitment activity visible and forecastable.

Pricing: Not publicly listed; sold as an enterprise site-and-sponsor platform, per OneStudyTeam's own site.

Best for: Sponsors and CRO teams that need shared, real-time enrollment visibility across a large, multi-site trial portfolio.

---

8. Inato: Free-for-Sites Trial Marketplace

Inato flips the usual sales model. Instead of charging community and mid-size research sites to access sponsor trials, it operates as a free marketplace: sites build a profile, get matched to trials that fit their patient population, and sponsors pay for access to a network of more than 5,000 sites across 50+ countries and 70+ disease areas.

Pricing: Free for research sites; sponsor access is negotiated, per Inato's own description of its free site marketplace.

Best for: Community and mid-size research sites wanting access to sponsor trials without paying a broker, and sponsors wanting to diversify beyond their usual site list.

---

9. Paradigm Health: Diversity Built Into the Provider Network

Paradigm Health launched with $203 million in Series A funding specifically to fix the diversity gap in trial recruitment, not as an afterthought bolted onto a general matching tool. Its platform links real-time EHR and genomic data across a research-ready network of 2,100 care locations, and it co-launched the PACT Collective with the CEO Roundtable on Cancer to align sponsors around FDA-style diversity goals.

Pricing: Not publicly listed; sold through sponsor and health-system partnership agreements, per Fierce Healthcare's coverage of Paradigm's launch.

Best for: Sponsors that need a formal, structured approach to diverse enrollment, especially with federal diversity guidance currently in limbo.

---

10. Antidote: Patient-Facing Trial Search at Scale

Antidote is the tool a patient or caregiver actually finds, not the one a coordinator uses behind the scenes. Antidote Match works as a public trial search engine embedded across more than 250 patient communities and health portals, reaching an estimated 15 million patients a month, with sponsors and advocacy organizations paying to distribute trial information through those trusted channels.

Pricing: Free for patients; sponsor recruitment marketing is quoted per campaign, per PatientPoint's coverage of the Antidote partnership.

Best for: Sponsors running patient-facing recruitment marketing, and patients or caregivers searching for trials directly.

---

11. Acclinate: Trust-Based Recruitment for Underrepresented Communities

Acclinate's argument is that diversity recruitment fails when it's just an algorithm mining EHR data for the right demographic checkboxes. Its NOWINCLUDED community, now around 200,000 members, is built by and for Black, Hispanic, and Indigenous communities specifically to build trust before a trial invitation ever arrives, paired with its e-DICT enrollment platform to convert that trust into actual participation.

Pricing: Not publicly listed; sold as a program-based engagement scoped to sponsor recruitment goals, per Acclinate's community-scaling announcement.

Best for: Sponsors and CROs that need genuine, trust-based recruitment into historically underrepresented communities, not just a demographic filter.

---

12. Unlearn.AI: Digital Twins to Shrink the Control Arm

Unlearn.AI solves a different problem than every other tool on this list: instead of finding more patients to enroll, it reduces how many you need. Its AI-generated digital twins forecast an individual trial participant's likely control-group outcome, which lets sponsors shrink control-arm enrollment, by roughly 20% to 50% in Unlearn's own analyses, while preserving statistical power.

Pricing: Not publicly listed; priced per trial engagement based on indication and design, per an independent overview of digital twins in trials.

Best for: Late-stage sponsors and biostatisticians looking to reduce control-arm size and total enrollment burden through trial design, not a recruitment tool in the traditional sense.

---

13. TrialGPT (NIH/NCI): The Open-Source Baseline Everyone Cites

TrialGPT isn't a company and it isn't for sale. It's an open-source, peer-reviewed algorithm built by researchers at the NIH's National Library of Medicine and National Cancer Institute, working with the University of Illinois Urbana-Champaign, University of Pittsburgh, and Albert Einstein College of Medicine. It works in three stages: retrieving candidate trials, scoring criterion-level eligibility, and ranking trials by fit, with faithful, explainable output at each step.

Pricing: Free and open-source; there is no vendor relationship or support contract, per the peer-reviewed study on PMC and NCI's own coverage.

Best for: Health systems, academic researchers, and engineering teams that want a free, published, independently validated starting point to build custom matching tools, rather than buying a commercial platform outright.

---

How to Choose: Decision Framework

By Access Model

---

AI in Patient Recruitment: HIPAA, IRB Oversight, and No Medical Advice

Nothing in this guide should be read as clinical, legal, or regulatory advice, and none of these tools replace an investigator's judgment or an IRB's authority over a protocol. They surface candidate matches and operational data; they do not determine eligibility, diagnose, or approve a patient for a study.

Three governance questions matter more than any feature comparison here. First, any tool touching identifiable patient data, structured or unstructured EHR fields, pathology notes, genomic data, needs a signed Business Associate Agreement and a clear commitment that patient data isn't used to train shared models without consent. Confirm this in writing before any patient-level data moves into a third-party system. Second, patient-facing recruitment materials and outreach language, including anything an AI tool generates or personalizes, typically still need IRB (or equivalent ethics committee) review before use, the same as any other recruitment material; if a pre-screening algorithm touches identifiable data as part of a study, IRB visibility into that process usually applies too. Third, where a tool produces or manages records that become part of the regulatory file, eConsent, audit trails tied to enrollment decisions, trial master file entries, those specific record-keeping components fall under 21 CFR Part 11 and need validated audit trails, access controls, and e-signature handling, even though the underlying matching or discovery step usually isn't itself a Part 11 record.

The diversity picture adds a fourth layer of uncertainty in 2026. The FDA's draft Diversity Action Plan guidance was pulled from the agency's website in 2025 without a finalized replacement, so sponsors currently have no single federal framework to point to, even as nearly 40% of the US population belongs to a racial or ethnic minority against 80% to 90% White trial participation. That's exactly the gap tools like Paradigm Health and Acclinate are built around, but it also means diversity commitments right now are voluntary and vendor-specific rather than regulator-mandated. If your organization is building broader AI governance beyond recruitment specifically, AI security and compliance and AI ethics and data privacy cover the controls worth having in place before any patient data touches a third-party AI system, and HIPAA-compliant marketing covers the parallel rules for any patient-facing outreach. The AI tool selection framework is a useful structure for comparing recruitment platforms on more than price, and healthcare marketing compliance is worth a read before any patient-facing recruitment campaign goes live.

Clinical and legal AI adoption are following a similar pattern in 2026: fast uptake, real efficiency gains, and governance that hasn't caught up. Our best AI tools for doctors guide covers the parallel story in direct patient care, and if general-purpose AI chat sits anywhere in your recruitment or protocol-drafting workflow, Claude vs ChatGPT vs Gemini is worth reading before defaulting to whichever model your organization already licenses.

Frequently Asked Questions

Related Reading

• Best AI Tools for Doctors in 2026: 12 Clinical AI Platforms Ranked by Use Case
• Best AI Tools in 2026: The Top 25 Across Every Category
• Best AI Tools for Lawyers in 2026: 12 Legal AI Platforms Ranked by Use Case
• Best AI Meeting Assistants and Notetakers in 2026
• Claude vs ChatGPT vs Gemini: Which LLM Fits Your Business in 2026
• AI Security and Compliance: Protect Your Business While Using AI Tools
• AI Ethics and Data Privacy: Responsible AI Productivity Tool Adoption
• AI Productivity Tool Selection: 6-Criteria Framework
• HIPAA-Compliant Marketing for Healthcare Practices
• Healthcare Marketing Compliance: Rules Every Practice Needs to Know
• Healthcare Technology Stack: Building an Integrated Practice Technology System

Methodology

Every tool on this list was evaluated on its actual recruitment function: EHR-based patient matching, oncology-specific chart abstraction and matching, site selection and feasibility, enrollment operations, marketplace access, diversity outreach, or trial-design methodology that reduces enrollment burden. Vendor claims were checked against the vendor's own announcements and, where available, independent or peer-reviewed coverage: Triomics' and Massive Bio's performance numbers come from press releases tied to peer-reviewed publications, TrialGPT's accuracy figures come from a study published via PMC (Nature Communications), and industry-wide enrollment and diversity statistics come from the University of California's research office, the Tufts Center for the Study of Drug Development, and FDA guidance summarized by RTI Health Solutions, each linked at first mention. Almost every enterprise vendor here withholds public pricing, a pattern stated plainly rather than filled in with invented numbers. This guide will be re-verified as new funding rounds, platform launches, and regulatory guidance continue to reshape this category through 2026.

What to Do Next

Start by identifying which job you actually need done, because these 13 tools solve different problems and almost none of them overlap completely. If you're a health system or large pharma sponsor needing EHR-scale matching, start with Tempus or ConcertAI and get a real pilot with your own data before signing a multi-year contract. If you're an academic cancer center, Triomics is worth a direct look given its adoption at peer institutions. If your patients are mostly in community oncology settings, Massive Bio's referral-network model fits better than an academic-center-first tool. If diversity is the priority, or if your organization is trying to build a formal enrollment plan while federal guidance is unsettled, start with Paradigm Health or Acclinate rather than bolting diversity onto a generic matching tool after the fact. And if your bottleneck is actually trial design and control-arm size rather than recruitment volume, Unlearn.AI addresses a different problem than every other tool on this list. Whatever you evaluate, get BAA terms, IRB implications, and any Part 11-relevant record-keeping in writing before a single patient's data moves into a new system.